OrthoPediatrics (FRA:2X7) LT-Debt-to-Total-Asset: 0.20 (As of Mar. 2026)

What is OrthoPediatrics LT-Debt-to-Total-Asset?

OrthoPediatrics FRA:2X7 -1.18% 77 LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus rates FRA:2X7 with a GF Score™ of 77/100 and a GF Value™ of €27.94. The stock has 5 warning signs investors should review.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. OrthoPediatrics's long-term debt to total assests ratio for the quarter that ended in Mar. 2026 was 0.20.

OrthoPediatrics's long-term debt to total assets ratio increased from Mar. 2025 (0.16) to Mar. 2026 (0.20). It may suggest that OrthoPediatrics is progressively becoming more dependent on debt to grow their business.

OrthoPediatrics (FRA:2X7) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

OrthoPediatrics LT-Debt-to-Total-Asset Related Terms

OrthoPediatrics LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for OrthoPediatrics's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OrthoPediatrics LT-Debt-to-Total-Asset Chart

OrthoPediatrics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.00

0.02

0.15

0.20

OrthoPediatrics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.16	0.19	0.20	0.20	0.20

77GF Score

OrthoPediatrics Corp FRA:2X7

LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

OrthoPediatrics LT-Debt-to-Total-Asset Calculation

OrthoPediatrics's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as

LT Debt to Total Assets (A: Dec. 2025 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2025 )	/	Total Assets (A: Dec. 2025 )
	=	85.246	/	434.37
	=	0.20

OrthoPediatrics's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2026 is calculated as

LT Debt to Total Assets (Q: Mar. 2026 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2026 )	/	Total Assets (Q: Mar. 2026 )
	=	86.835	/	434.394
	=	0.20

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →

What does a LT-Debt-to-Total-Asset of 0.20 mean?

OrthoPediatrics (FRA:2X7) has a LT-Debt-to-Total-Asset of 0.20 as of Mar. 2026. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OrthoPediatrics and its competitors.

Is OrthoPediatrics' LT-Debt-to-Total-Asset too high?

OrthoPediatrics' current LT-Debt-to-Total-Asset is 0.20. Overall, OrthoPediatrics has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.

How does OrthoPediatrics' LT-Debt-to-Total-Asset compare to PACB and CLPT?

OrthoPediatrics' LT-Debt-to-Total-Asset of 0.20 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good LT-Debt-to-Total-Asset for a Medical Devices & Instruments company?

A good LT-Debt-to-Total-Asset depends on the Medical Devices & Instruments industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high LT-Debt-to-Total-Asset mean?

A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on OrthoPediatrics and its competitors. OrthoPediatrics's current LT-Debt-to-Total-Asset is 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is OrthoPediatrics stock overvalued right now?

OrthoPediatrics (FRA:2X7) has a current LT-Debt-to-Total-Asset of 0.20. The stock's GF Value™ is €27.94, compared to a current price of €17.00 — trading 39.2% below its estimated fair value. The current LT-Debt-to-Total-Asset is 0.20. OrthoPediatrics' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is LT-Debt-to-Total-Asset calculated?

LT-Debt-to-Total-Asset is calculated from a company's financial statements. For OrthoPediatrics (FRA:2X7), the current LT-Debt-to-Total-Asset is 0.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is OrthoPediatrics (FRA:2X7) Overvalued in 2026?

Based on GuruFocus' analysis, OrthoPediatrics stock appears to be undervalued. The current stock price of €17.00 is trading 39.2% below its estimated GF Value™ of €27.94.

Key valuation signals for FRA:2X7:

LT-Debt-to-Total-Asset: 0.20
GF Value™: €27.94 vs. price of €17.00 (39.2% below fair value)
GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the FRA:2X7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

OrthoPediatrics Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies PACB CLPT MOBI NPCE SI CTKB CERS DCTH VMD VREX ABT SYK MDT BSX EW XTER:SHL GEHC DXCM XAMS:PHIA SZSE:300760

Other Exchanges KIDS:USA

Address 2850 Frontier Drive, Warsaw, IN, USA, 46582

Website https://www.orthopediatrics.com

OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.

77GF Score

Get the complete analysis for FRA:2X7

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.00

Price

€27.94

GF Value

View FRA:2X7 Analysis

See LT-Debt-to-Total-Asset data for all stocks →